Objective: Gut microbiota have been linked to inflammatory bowel disease (IBD) and colorectal cancer (CRC). () is a gram-negative anaerobic bacterium that is selectively decreased in the faecal microbiota of patients with IBD, but its causative role and molecular mechanism in blunting colitis-associated colorectal cancer (CAC) remain inconclusive. This study investigates how engages the immune response in CAC.
Design: Mice were given dextran sulfate sodium to induce colitis, followed by azoxymethane to establish CAC with or without pasteurised or a specific outer membrane protein (Amuc_1100) treatment. Faeces from mice and patients with IBD or CRC were collected for 16S rRNA sequencing. The effects of or Amuc_1100 on the immune response in acute colitis and CAC were investigated.
Results: was significantly reduced in patients with IBD and mice with colitis or CAC. or Amuc_1100 could improve colitis, with a reduction in infiltrating macrophages and CD8 cytotoxic T lymphocytes (CTLs) in the colon. Their treatment also decreased CD16/32 macrophages in the spleen and mesenteric lymph nodes (MLN) of colitis mice. Amuc_1100 elevated PD-1 CTLs in the spleen. Moreover, and Amuc_1100 blunted tumourigenesis by expanding CTLs in the colon and MLN. Remarkably, they activated CTLs in the MLN, as indicated by TNF-α induction and PD-1downregulation. Amuc_1100 could stimulate and activate CTLs from splenocytes in CT26 cell conditioned medium.
Conclusions: These data indicate that pasteurised or Amuc_1100 can blunt colitis and CAC through the modulation of CTLs.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7569398 | PMC |
http://dx.doi.org/10.1136/gutjnl-2019-320105 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!